Beate Heissig

Dr. Beate Heissig

Biomedical Research Core Facilities, Juntendo University, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2001 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DLDavid Lyden
David Lyden
KHKoichi Hattori
Koichi Hattori
Sérgio DiasSérgio Dias
Sérgio Dias
CCCarla Costa
Carla Costa
PBPamela Blaikie
Pamela Blaikie
SRShahin Rafii
Shahin Rafii

1 May 2002 in Cell
Verified
Journal Article
Closed access
Beate HeissigBeate Heissig
Beate Heissig
KHKoichi Hattori
Koichi Hattori
Sérgio DiasSérgio Dias
Sérgio Dias
MFMatthias Friedrich
Matthias Friedrich
BFBarbara Ferris
Barbara Ferris
SRShahin Rafii
Shahin Rafii

21 December 2003 in Nature Medicine
Verified
Journal Article
Closed access
SAScott T Avecilla
Scott T Avecilla
KHKoichi Hattori
Koichi Hattori
Beate HeissigBeate Heissig
Beate Heissig
RTRafael Tejada
Rafael Tejada
FLFang Liao
Fang Liao
SRShahin Rafii
Shahin Rafii

1 November 2002 in Nature Reviews Cancer
Verified
Journal Article
Closed access
SRShahin Rafii
Shahin Rafii
DLDavid Lyden
David Lyden
RBRobert Benezra
Robert Benezra
KHKoichi Hattori
Koichi Hattori
Beate HeissigBeate Heissig
Beate Heissig

30 April 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KHKoichi Hattori
Koichi Hattori
Sérgio DiasSérgio Dias
Sérgio Dias
Beate HeissigBeate Heissig
Beate Heissig
NHNeil R. Hackett
Neil R. Hackett
DLDavid Lyden
David Lyden
SRShahin Rafii
Shahin Rafii
Tyrosine kinase receptors for angiogenic factors vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) are expressed not only by endothelial cells but also by subsets of hematopoietic stem cells (HSCs). To further define their role in the regulation of postnatal hematopoiesis and vasculogenesis, VEGF and Ang-1 plasma levels were elevated by injecting recombinant protein or adenoviral vectors expressing soluble VEGF165, matrix-bound VEGF189, or Ang-1 into mice. VEGF165, but not VEGF189, induced a rapid mobilization of HSCs and VEGF receptor (VEGFR)2+ circulating endothelial precursor cells (CEPs). In contrast, Ang-1 induced delayed mobilization of CEPs and HSCs. Combined sustained elevation of Ang-1 and VEGF165 was associated with an induction of hematopoiesis and increased marrow cellularity followed by proliferation of capillaries and expansion of sinusoidal space. Concomitant to this vascular remodeling, there was a transient depletion of hematopoietic activity in the marrow, which was compensated by an increase in mobilization and recruitment of HSCs and CEPs to the spleen resulting in splenomegaly. Neutralizing monoclonal antibody to VEGFR2 completely inhibited VEGF165, but not Ang-1–induced mobilization and splenomegaly. These data suggest that temporal and regional activation of VEGF/VEGFR2 and Ang-1/Tie-2 signaling pathways are critical for mobilization and recruitment of HSCs and CEPs and may play a role in the physiology of postnatal angiogenesis and hematopoiesis.

30 April 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DJDavid K Jin
David K Jin
KSKoji Shido
Koji Shido
HKHans-Georg Kopp
Hans-Georg Kopp
IPIsabelle Petit
Isabelle Petit
SSSergey V Shmelkov
Sergey V Shmelkov
SRShahin Rafii
Shahin Rafii